{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol&page=2", "query": { "intervention": "Estradiol", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T09:46:49.237Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00534417", "title": "Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2007-10", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 10, "location_summary": "Miami, Florida • Athens, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00534417" }, { "nct_id": "NCT00694733", "title": "Regulation of Cortisol Metabolism and Fat Patterning", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Menopausal Syndrome" ], "interventions": [ { "name": "Placebo injection", "type": "DRUG" }, { "name": "Depo Lupron/Aromatase inhibitor", "type": "DRUG" }, { "name": "Depo Lupron/placebo", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Estrogen cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "62 Years", "sex": "ALL", "summary": "18 Years to 62 Years" }, "enrollment_count": 140, "start_date": "2005-05", "completion_date": "2024-09", "has_results": false, "last_update_posted_date": "2022-12-16", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694733" }, { "nct_id": "NCT00005108", "title": "Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerosis", "Healthy", "Vascular Disease" ], "interventions": [ { "name": "Estradiol", "type": "DRUG" }, { "name": "Progesterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 25, "start_date": "2000-04", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005108" }, { "nct_id": "NCT02080468", "title": "Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "lomitapide", "type": "DRUG" }, { "name": "EE/norgestimate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aegerion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 32, "start_date": "2014-02-19", "completion_date": "2014-04-24", "has_results": true, "last_update_posted_date": "2019-03-11", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02080468" }, { "nct_id": "NCT05538689", "title": "Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metrorrhagia", "Pelvic Pain", "Menorrhagia", "Leiomyoma" ], "interventions": [ { "name": "Myfembree Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-11-20", "completion_date": "2024-10-24", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 6, "location_summary": "Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Flossmoor", "state": "Illinois" }, { "city": "Orland Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538689" }, { "nct_id": "NCT06408168", "title": "Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Receptor-positive Human Epidermal Growth Factor 2-negative", "Metastatic Invasive LObular Carcinoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Repotrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-08-08", "completion_date": "2025-12-08", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06408168" }, { "nct_id": "NCT02316249", "title": "Vaginal Creams to Reduce Vaginal Erosion in Pessary Users", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atrophy of Vagina", "Vaginal Ulceration", "Vaginitis" ], "interventions": [ { "name": "Estradiol", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2015-04", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-10-02", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Great Neck, New York", "locations": [ { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02316249" }, { "nct_id": "NCT00149604", "title": "AFTER: Altering Fat Through Estrogen and Raloxifene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postmenopause" ], "interventions": [ { "name": "conjugated estrogens", "type": "DRUG" }, { "name": "Raloxifene", "type": "DRUG" }, { "name": "exercise plus mild caloric restriction for weight loss", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "National Institute on Aging (NIA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "50 Years to 70 Years · Female only" }, "enrollment_count": 108, "start_date": "2000-03", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2009-12-02", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00149604" }, { "nct_id": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "HER2-Positive Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Denifanstat", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-08-03", "completion_date": "2026-03-13", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179904" }, { "nct_id": "NCT03584009", "title": "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 103, "start_date": "2018-09-06", "completion_date": "2021-05-06", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-21T09:46:49.237Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03584009" } ] }